Nutricin Hospitalaria, 36 (6), 14241429
Clinical evidence suggests that combined SGLT2i and GLP-1 RA therapy is additive in terms of lowering HbA1c levels, systolic blood pressure, and body weight
Researchers are excited about Trevogrumab and Garetosmab for obesity because these treatments represent a novel approach compared to existing options like lifestyle changes, medications such as orlistat, and GLP-1 agonists like semaglutide
People with prediabetes, diabetes, or family history of diabetes should be particularly vigilant
NAC Dosing (as Glutathione Precursor) General antioxidant support: 600-1,200 mg/day in divided doses [9][18] Respiratory conditions (COPD): 600-1,200 mg/day (PANTHEON trial used 600 mg twice daily) [43][44] Psychiatric conditions: 1,200-2,400 mg/day (most trials used 2,000-2,400 mg/day) [72][73][74] Male fertility: 600 mg/day [69] Immune support in elderly: 600-1,200 mg/day [40] GlyNAC Dosing The Kumar et al